Navitoclax

CAS No. 923564-51-6

Navitoclax ( ABT-263;ABT 263;ABT263 )

Catalog No. M16614 CAS No. 923564-51-6

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 37 In Stock
10MG 51 In Stock
25MG 79 In Stock
50MG 133 In Stock
100MG 177 In Stock
200MG 259 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Navitoclax
  • Note
    Research use only, not for human use.
  • Brief Description
    Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w.
  • Description
    Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor with Ki of <1 nM for Bcl-2, Bcl-xL, and Bcl-w; binds more weakly to Mcl-1 and A1 (Ki>350 nM); disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), induces apoptosis, shows cellular activity against a panel of human tumor cell lines (EC50<1 uM); induces complete tumor regressions in xenograft models of NSCLA and ALL.Blood Cancer Phase 2 Clinical
  • Synonyms
    ABT-263;ABT 263;ABT263
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2;Bcl-w;Bcl-xL
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    923564-51-6
  • Formula Weight
    974.61
  • Molecular Formula
    C47H55ClF3N5O6S3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
  • Chemical Name
    Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8.
2. Shoemaker AR, et al. Clin Cancer Res. 2008 Jun 1;14(11):3268-77.
3. Ackler S, et al. Mol Cancer Ther. 2008 Oct;7(10):3265-74.
4. Shah OJ, et al. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9.
molnova catalog
related products
  • Orobol

    Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.

  • (-) BI97D6

    (-) BI97D6 (BI112D1) is a potent, pan-active inhibitor of Bcl-2 family proteins with IC50 of 76, 31, 25, and 122 nM for Bcl-xL, Bcl-2, Mcl-1, and Bfl-1, respectively.

  • MIK665

    MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.